Schilke Tobin 4
4 · Crinetics Pharmaceuticals, Inc. · Filed Feb 25, 2026
Insider Transaction Report
Form 4
Schilke Tobin
Chief Financial Officer
Transactions
- Award
Common Stock
[F1][F2]2026-02-23+32,000→ 84,834 total - Award
Stock Option (Right to Buy)
[F3]2026-02-23+50,000→ 50,000 totalExercise: $43.79Exp: 2036-02-23→ Common Stock (50,000 underlying)
Footnotes (3)
- [F1]The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 1, 2027.
- [F2]Includes 834 shares acquired under the Issuer's Employee Stock Purchase Plan.
- [F3]The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 23, 2026.
Signature
/s/ Tobin Schilke|2026-02-25